PATENT CLAIM ANALYSIS

Application Number: 15986577
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "364000"]

Abstract:
Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Claim (Index 61):
The method of  claim 60  wherein the disease is selected from the group consisting of breast cancer, prostate cancer, cervical cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies, melanoma and sarcomas.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.43333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13980208', '13983887', '15294157', '13979955', '14005680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8855572050796591
- 35 USC 102 Novelty (BERT): 0.6387028360670144
- Combined Prediction Score: 0.8608717681783946
- Mean Citation Score: 686.2745000000001
- Max Citation Score: 729.4968
- Similarity Product: 538.1089932343483

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test